CRYO-CELL INTERNATIONAL, INC. (CCEL) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-05-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-05-31..
- Interest coverage · 12 months: Value -0.05×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | -0.05× | Operating income ÷ reported interest expense. $-103.78K ÷ $1.92M ≈ -0.05× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 311.95K USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 303.14K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -103.78K USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 1.92M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $311.95K | (m) | $303.14K | $-103.78K | $1.92M | (m) | (m) | -0.05× | Reported |
| 2026-02-28 | $343.88K | (m) | $278.26K | $191.52K | $2.03M | (m) | (m) | 0.09× | Reported |
| 2025-11-30 | $376.26K | (m) | $417.10K | $482.39K | $2.07M | (m) | (m) | 0.23× | Reported |
| 2025-08-31 | $596.11K | (m) | $523.89K | $4.33M | $2.33M | (m) | (m) | 1.86× | Reported |
| 2025-05-31 | $728.42K | (m) | $633.05K | $3.82M | $2.33M | (m) | (m) | 1.64× | Reported |
| 2025-02-28 | $837.79K | (m) | $771.16K | $3.72M | $2.10M | (m) | (m) | 1.77× | Reported |
| 2024-11-30 | $1.24M | (m) | $781.13K | $3.48M | $1.86M | (m) | (m) | 1.87× | Reported |
| 2024-08-31 | $1.38M | (m) | $806.38K | $-12.57M | $950.16K | (m) | (m) | -13.23× | Reported |
| 2024-05-31 | $1.53M | (m) | $832.54K | $-12.80M | $886.34K | (m) | (m) | -14.44× | Reported |
| 2024-02-29 | $1.60M | (m) | $810.82K | $-13.17M | $1.03M | (m) | (m) | -12.82× | Reported |
| 2023-11-30 | $1.17M | (m) | $816.64K | $-12.30M | $1.24M | (m) | (m) | -9.95× | Reported |
| 2023-08-31 | $804.05K | (m) | $792.59K | $4.28M | $1.98M | (m) | (m) | 2.16× | Reported |
| 2023-05-31 | $540.19K | (m) | $781.58K | $4.07M | $1.88M | (m) | (m) | 2.17× | Reported |
| 2023-02-28 | $316.40K | (m) | $742.62K | $4.24M | $1.68M | (m) | (m) | 2.52× | Reported |
| 2022-11-30 | $384.79K | (m) | $461.35K | $4.02M | $1.52M | (m) | (m) | 2.64× | Reported |
| 2022-08-31 | $338.83K | (m) | $378.19K | $2.80M | $1.37M | (m) | (m) | 2.04× | Reported |
| 2022-05-31 | $268.56K | (m) | $298.40K | $3.44M | $1.34M | (m) | (m) | 2.57× | Reported |
| 2022-02-28 | $190.90K | (m) | $248.69K | $4.24M | $1.40M | (m) | (m) | 3.02× | Reported |
| 2021-11-30 | $49.87K | (m) | $301.62K | $4.00M | $1.38M | (m) | (m) | 2.90× | Reported |
| 2021-08-31 | $26.49K | (m) | $405.24K | $7.01M | $1.43M | (m) | (m) | 4.89× | Reported |
| 2021-05-31 | $17.73K | (m) | $485.94K | $7.89M | $1.43M | (m) | (m) | 5.50× | Reported |
| 2021-02-28 | $24.32K | (m) | $482.68K | $7.65M | $1.46M | (m) | (m) | 5.24× | Reported |
| 2020-11-30 | $23.85K | (m) | $622.12K | $7.66M | $1.54M | (m) | (m) | 4.96× | Reported |
| 2020-08-31 | $33.66K | (m) | $608.53K | $7.20M | $1.53M | (m) | (m) | 4.71× | Reported |
| 2020-05-31 | $34.85K | (m) | $460.71K | $6.71M | $1.60M | (m) | (m) | 4.19× | Reported |
| 2020-02-29 | $29.98K | (m) | $483.05K | $5.46M | $1.66M | (m) | (m) | 3.28× | Reported |
| 2019-11-30 | $30.14K | (m) | $397.77K | $5.06M | $1.70M | (m) | (m) | 2.97× | Reported |
| 2019-08-31 | $40.20K | (m) | $394.56K | $5.48M | $1.80M | (m) | (m) | 3.05× | Reported |
| 2019-05-31 | $59.99K | (m) | $435.80K | $4.40M | $1.79M | (m) | (m) | 2.46× | Reported |
| 2019-02-28 | $84.32K | (m) | $61.77K | $5.06M | $1.67M | (m) | (m) | 3.02× | Reported |
| 2018-11-30 | $91.84K | (m) | $478.38K | $5.19M | $1.55M | (m) | (m) | 3.35× | Reported |
| 2018-08-31 | $82.41K | (m) | $586.36K | $4.30M | $1.36M | (m) | (m) | 3.16× | Reported |
| 2018-05-31 | $60.40K | $26.12M | $769.10K | $4.83M | $1.27M | 0.23% | 2.94% | 3.82× | Reported |
| 2018-02-28 | $39.96K | $25.84M | $1.45M | $4.88M | $1.29M | 0.15% | 5.61% | 3.79× | Reported |
| 2017-11-30 | $41.16K | $25.38M | $971.73K | $5.01M | $1.30M | 0.16% | 3.83% | 3.84× | Reported |
| 2017-08-31 | $42.33K | $24.78M | $1.66M | $4.22M | $1.08M | 0.17% | 6.70% | 3.90× | Reported |
| 2017-05-31 | $55.88K | $24.22M | $1.86M | $1.70M | $964.90K | 0.23% | 7.66% | 1.77× | Reported |
| 2017-02-28 | $59.03K | $23.75M | $1.60M | $1.39M | $983.05K | 0.25% | 6.72% | 1.42× | Reported |
| 2016-11-30 | $53.10K | $23.13M | $1.77M | $433.59K | $947.34K | 0.23% | 7.66% | 0.46× | Reported |
| 2016-08-31 | $47.76K | $23.06M | $1.12M | $418.36K | $1.08M | 0.21% | 4.86% | 0.39× | Reported |
| 2016-05-31 | $43.93K | $22.16M | $746.17K | $2.74M | $1.24M | 0.20% | 3.37% | 2.22× | Reported |
| 2016-02-29 | $42.48K | $21.40M | $664.78K | $2.46M | $1.26M | 0.20% | 3.11% | 1.95× | Reported |
| 2015-11-30 | $45.78K | $21.09M | $602.98K | $2.93M | $1.30M | 0.22% | 2.86% | 2.25× | Reported |
| 2015-08-31 | $46.30K | $20.27M | $453.44K | $2.68M | $1.34M | 0.23% | 2.24% | 2.00× | Reported |
| 2015-05-31 | $54.20K | $19.77M | $441.31K | $1.84M | $1.30M | 0.27% | 2.23% | 1.42× | Reported |
| 2015-02-28 | $61.99K | $19.65M | $442.51K | $1.80M | $1.18M | 0.32% | 2.25% | 1.53× | Reported |
| 2014-11-30 | $64.37K | $20.13M | $404.23K | $1.98M | $1.15M | 0.32% | 2.01% | 1.72× | Reported |
| 2014-08-31 | $60.59K | $19.86M | $302.16K | $2.26M | $1.41M | 0.31% | 1.52% | 1.61× | Reported |
| 2014-05-31 | $50.87K | $19.75M | $317.96K | $2.42M | $1.41M | 0.26% | 1.61% | 1.71× | Reported |
| 2014-02-28 | $39.62K | $19.72M | $334.25K | $1.94M | $1.42M | 0.20% | 1.70% | 1.37× | Reported |
| 2013-11-30 | $36.17K | $18.99M | $271.96K | $1.70M | $1.40M | 0.19% | 1.43% | 1.22× | Reported |
| 2013-08-31 | $47.30K | $19.11M | $476.84K | $686.52K | $1.07M | 0.25% | 2.49% | 0.64× | Reported |
| 2013-05-31 | $105.21K | $18.82M | $467.70K | $142.43K | $958.76K | 0.56% | 2.48% | 0.15× | Reported |
| 2013-02-28 | $105.98K | $18.39M | $1.16M | $-1.07M | $973.80K | 0.58% | 6.28% | -1.10× | Reported |
| 2012-11-30 | $109.64K | $17.97M | $1.33M | $-1.71M | $1.02M | 0.61% | 7.37% | -1.67× | Reported |
| 2012-08-31 | $104.00K | $17.58M | $995.29K | $-853.09K | $1.04M | 0.59% | 5.66% | -0.82× | Reported |
| 2012-05-31 | $90.19K | $17.45M | $1.26M | $-2.79M | $1.24M | 0.52% | 7.19% | -2.25× | Reported |
| 2012-02-29 | $163.00K | $17.62M | $529.33K | $-1.04M | $1.36M | 0.92% | 3.00% | -0.76× | Reported |
| 2011-11-30 | $184.05K | $17.92M | $329.00K | $-276.74K | $1.46M | 1.03% | 1.84% | -0.19× | Reported |
| 2011-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-02-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-11-30 | $132.99K | $17.76M | $128.09K | $3.35M | $1.28M | 0.75% | 0.72% | 2.60× | Reported |
| 2010-08-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |